On Friday 6 June, the European Commission issued a conditional EU marketing authorisation for givinostat (Duvyzat), a drug designed to treat Duchenne muscular dystrophy.
There is currently no cure for this rare genetic disease, characterised by progressive muscle weakness and deterioration, mainly in children.
Authorisation is based on a positive scientific assessment by the European Medicines Agency (EMA).
The EMA concluded that, although all the data is not yet available, the benefits to...